Alexion pushes for judgment in EmblemHealth's US antitrust suit over Soliris
( September 21, 2026, 16:15 GMT | Official Statement) -- MLex Summary: Alexion Pharmaceuticals filed a reply in support of its motion for judgment on pleadings in EmblemHealth's US antitrust suit over Alexion's alleged unlawful delaying of biosimilar competition for its drug Soliris, which treats rare blood and immune disorders. Alexion said Emblem can't establish its standing to assert a sham litigation claim based on the exact same allegations of fraud on the Patent and Trademark Office that the court has already held are “too far removed from Emblem’s injuries.”See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.